Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Heart failure is a major cause of death, hospital admissions and poor quality of life. It affects some 1-2% of the general population, increasing to up to 8% in people over 75 years of age. Although treatment with angiotensin-converting enzyme (ACE) inhibitors reduces symptoms and mortality, 50-70% of patients with heart failure still die within 5 years of diagnosis. There is thus clear scope for improving the treatment of patients with this condition. The CHARM programme is designed to define the clinical benefits of the long-acting angiotensin II type 1 (AT 1 ) receptor blocker, candesartan cilexetil, in a wide variety of patients with symptomatic heart failure. Candesartan cilexetil will be evaluated in three double-blind, randomized studies involving patients grouped according to left ventricular function and ACE inhibitor tolerance/intolerance. © 2000, Informa UK Ltd All rights reserved: reproduction in whole or part not permitted. All rights reserved.

Cite

CITATION STYLE

APA

Swedberg, K., Pfeffer, M., Granger, G. B., Mcmurray, J., & Yusuf, S. (2000). Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme. Blood Pressure, 9(1), 60. https://doi.org/10.1080/080370500439335

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free